100 year life span: coming soon ???

100-yr life span to be common soon Deccan Chronicle 2011-01-27


Hyderabad, Jan. 26: Satapoorti, or celebration of a person’s 100th birthday will become common in the next three decades as the average life span of people increases by 20 years, says eminent geneticist and biotechnologist Dr Krishna Dronamraju.
“It is only a matter of time. In the next 30 years, the average life span will increase by at least 15 years, if not 20 years. Once this happens, Sashtipoorti (celebration of 60th birthday) will be passé. Satapoorti will be the in-thing, as many people will live beyond 100,” Dr Dronamraju said.

Sashtipoorti was celebrated because any one living beyond 50 years was considered a miracle and thus warranted a celebration. Now that most people live beyond the age of 70, Sashtipoorti has lost its flavour.
“We should now look forward to Satapoorti,” said the India-born scientist who now lives in the United States.
Dr Dronamraju, who is also an adviser to the US government on health and agriculture, says the average life span has increased by 20 years in the last 50 years, and with pioneering research in genetics, stem cells and nanotechnology, people may live beyond 100 years.
Advanced gene therapy will help in strengthening the heart muscles so that it can work longer.
Strengthening heart, lungs, blood vessels and kidneys through gene therapy will improve not only the quality of life, but also the overall life span.

At best, a human being can live up to 150 years. “There’s a lot of wear and tear in the body, but we can postpone death. An artificial heart is almost a reality. Considerable research has been done in lung transplant. Once artificial heart and lung transfer become practical, we can prolong human life.”

Many people living in the Caucasus Mountains are known to live beyond 100 years, Dr Dronamraju said. Research studies show that these people avoid fatty substances in their diet. “The body needs a lot of dietary fibre and the best source is through vegetables and fruits,” he said, providing the recipe for a long and healthy life

Wearable Kidney will a Wearable lung be next ?

Wearable Kidney will a Wearable lung be next ?

 

Wearable Kidney

For people with failing kidneys, basic necessities of life like removing toxins from the blood and keeping fluid levels balanced requires hours hooked up to a dialysis machine the size of a clothes dryer. But a new, portable artificial kidney, small and light enough to fit on a belt system, could change that. Despite its small size, the automated, wearable artificial kidney (AWAK), designed by Martin Roberts and David B.N. Lee of UCLA, actually works better than traditional dialysis because it can be used 24 hours a day, seven days a week, just like a real kidney.

 

 

 

see the top 10 Bionic tech devices

Novalung and Medos start cooperation

Due to the acquisition of Medos Medizintechnik AG by the private equity fund Zukunftsfonds Heilbronn (“Future Fund of Heilbronn”) the company will cooperate closely in the future with Novalung GmbH, which is expected to strengthen both medical device companies.

The Zukunftsfonds Heilbronn (zfhn) announced that it has acquired Medos Medizintechnik AG from Ventizz Capital Partners Advisory AG. The purchase agreement was signed on January 7, 2011. With this acquisition medical device technology has become the most important sector for the private equity fund. Thomas Villinger, Managing Director of the zfhn, explained the decision behind this acquisition: ”The medical device sector is characterized by solid growth and is independent of economic cycles.“ He noted further that “Medos and Novalung are technological leaders is different markets, namely cardiac support and lung support. Their innovative technologies complement one another extremely well, and a close cooperation will enable even better utilization and speed up further developments.“

Dr. Volker Hamm, who has been named to join the Medos Management Board, noted with pleasure: “We are very happy about this development. Novalungs excellent market know-how in the field of lung support will provide a much broader customer base for our high-tech products.“ Hamm also noted that Christian Palme will join Thomas Villinger on the Supervisory Board of Medos. The Medos facilities in Stolberg und Radeberg will continue their operations after the acquisition.

Dr. Georg Matheis, Managing Director of Novalung GmbH since its founding eight years ago, emphasized that Novalung, after thousands of treatments using the company’s artificial lung, the iLA Membrane Ventilator®, has firmly established itself. “The innovative therapy for the treatment of lung failure without invasive mechanical ventilation is now well accepted” the former cardiothoracic surgeon noted. ”In order to further expand our market leadership as the pioneering company in this field, we will develop a full product portfolio in 2011. With the cooperation with Medos this can be accomplished more quickly than we originally expected.“ Matheis also pointed to the newest member of Novalung’s executive management team, Josef Bogenschütz, who left medical device company Maquet and join Novalung just a few weeks earlier. “In addition to strong leadership, Josef Bogenschütz brings with him great expertise in the development and manufacturing of artificial lungs. With him on board we are ideally positioned to aggressively develop additional innovative solutions for the replacement of invasive mechanical ventilation. Together, and with the support of our clinical partners, we will realize the vision of increasingly avoiding the damage of invasive mechanical ventilation.“

Bogenschütz, who most recently drove the successful growth of Maquet Cardiopulmonary AG as President and CEO, is equally optimistic concerning the expansion of the zfhn portfolio. ”I am pleased that this new cooperation provides so many areas of synergy for both companies. We will jointly leverage our know-how in the high-end cleanroom manufacturing of artificial lungs to further optimize our manufacturing efficiencies.“ He also presented Novalungs core strategy to intensify the company’s research and development activities and to further expand sales in the core markets in Europe and the USA.

see more info on this external lung device
http://www.openpr.com/news/159889/Novalung-and-Medos-start-cooperation.html

new Manager at Novalung GmbH a artificial lungs manufacturer

Novalung GmbH prepares for further growth with former Maquet CEO.

As of January 1, 2011, Josef Bogenschütz and Dr. Georg Matheis are joint Managing Directors of Novalung GmbH. Bogenschütz will be specifically responsible for Research & Development, Manufacturing, Quality Management and Finance. This addition underscores the company’s focus on the ongoing and efficient expansion of its portfolio of innovative products designed to replace invasive mechanical ventilation. Nicholas L. Strout remains responsible for the growth of Novalung’s sales activities.

Dr. Georg Matheis, who has been Managing Director of Novalung since its founding in 2003, commented: “I’m truly looking forward to working with Josef Bogenschütz, who brings with him extensive expertise in our core business, the development and manufacturing of artificial lungs.“